By SPC News Staff
Thousands of women with the most common form of early stage breast cancer who receive hormone therapy may not need adjuvant chemotherapy, according to a study presented today at the 2018 American Society of Clinical Oncology annual meeting.
TAILORx (Trial Assigning Individualized Options for Treatment was one of the first large-scale trials to examine a methodology for personalizing cancer treatment.
The results showed that most women with hormone receptor (HR)-positive, human